Johnston CI - Search Results

1

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy.

Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, Cooper ME, Allen TJ. Davis BJ, et al. Among authors: johnston ci. Diabetologia. 2003 Jul;46(7):961-71. doi: 10.1007/s00125-003-1121-9. Epub 2003 Jun 28. Diabetologia. 2003. PMID: 12838387

2

Angiotensin converting enzyme inhibitors in perspective: an update.

Burrell LM, Johnston CI. Burrell LM, et al. Among authors: johnston ci. Aust Fam Physician. 1993 Jul;22(7):1243-7, 1251, 1255. Aust Fam Physician. 1993. PMID: 8373316 Review.

3

Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.

Hulthén UL, Cao Z, Rumble JR, Cooper ME, Johnston CI. Hulthén UL, et al. Among authors: johnston ci. Am J Hypertens. 1996 Sep;9(9):895-901. doi: 10.1016/s0895-7061(96)00177-x. Am J Hypertens. 1996. PMID: 8879346

4

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus.

Tikkanen T, Tikkanen I, Rockell MD, Allen TJ, Johnston CI, Cooper ME, Burrell LM. Tikkanen T, et al. Among authors: johnston ci. Hypertension. 1998 Oct;32(4):778-85. doi: 10.1161/01.hyp.32.4.778. Hypertension. 1998. PMID: 9774379

5

Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure.

Burrell LM, Farina NK, Balding LC, Johnston CI. Burrell LM, et al. Among authors: johnston ci. Hypertension. 2000 Dec;36(6):1105-11. doi: 10.1161/01.hyp.36.6.1105. Hypertension. 2000. PMID: 11116133

6

Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.

Kubota E, Dean RG, Hubner RA, Balding LC, Johnston CI, Burrell LM. Kubota E, et al. Among authors: johnston ci. Curr Hypertens Rep. 2001 Dec;3 Suppl 2:S31-3. doi: 10.1007/s11906-001-0105-8. Curr Hypertens Rep. 2001. PMID: 11716804 Review.

7

In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat.

Hubner RA, Kubota E, Casley DJ, Johnston CI, Burrell LM. Hubner RA, et al. Among authors: johnston ci. J Hypertens. 2001 May;19(5):941-6. doi: 10.1097/00004872-200105000-00015. J Hypertens. 2001. PMID: 11393678

8

ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes.

Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME, Thomas MC. Tikellis C, et al. Diabetes. 2008 Apr;57(4):1018-25. doi: 10.2337/db07-1212. Epub 2008 Jan 30. Diabetes. 2008. PMID: 18235039

9

Angiotensin-converting enzyme 2 regulates renal atrial natriuretic peptide through angiotensin-(1-7).

Bernardi S, Burns WC, Toffoli B, Pickering R, Sakoda M, Tsorotes D, Grixti E, Velkoska E, Burrell LM, Johnston C, Thomas MC, Fabris B, Tikellis C. Bernardi S, et al. Clin Sci (Lond). 2012 Jul;123(1):29-37. doi: 10.1042/CS20110403. Clin Sci (Lond). 2012. PMID: 22288735

10

Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.

Burrell LM, Phillips PA, Risvanis J, Aldred KL, Hutchins AM, Johnston CI. Burrell LM, et al. Among authors: johnston ci. Hypertension. 1995 Nov;26(5):828-34. doi: 10.1161/01.hyp.26.5.828. Hypertension. 1995. PMID: 7591025

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

423 results

Search Page

Filters